Robert J. Motzer,
Bernard Escudier,
Piotr Tomczak,
Thomas E. Hutson,
M. Dror Michaelson,
Sylvie Negrier,
Stephane Oudard,
Martin E. Gore,
Jamal Tarazi,
Subramanian Hariharan,
Connie Chen,
Brad Rosbrook,
Sinil Kim,
Brian I. Rini,
Bernard Escudier,
Piotr Tomczak,
Thomas E. Hutson,
M. Dror Michaelson,
Sylvie Negrier,
Stephane Oudard,
Martin E. Gore,
Jamal Tarazi,
Subramanian Hariharan,
Connie Chen,
Brad Rosbrook,
Sinil Kim,
Brian I. Rini,
- Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial. Motzer, R.J., Escudier, B., Tomczak, P., Hutson, T.E., Michaelson, M.D., Negrier, S., Oudard, S., Gore, M.E., Tarazi, J., Hariharan, S., Chen, C., Rosbrook, B., Kim, S., Rini, B.I. Lancet Oncol. (2013)